drugset / Trial / NCT00136487
Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer
Phase 2/3
Completed
85 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabEmerson Hospital, Concord, MA · collabHartford Hospital · collabLowell General Hospital · collabM.D. Anderson Cancer Center · collabMassachusetts General Hospital · collabPfizer · collabUniversity of Michigan Rogel Cancer Center · collab
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this study is to learn the effects (both good and bad) that celecoxib has on prostate cancer and patients with prostate cancer. This study is looking at what effects celecoxib has on prostate specific antigen (PSA) level. PSA is a marker specific to prostate cancer. An increase or decrease in this level in the blood can indicate if a patient's prostate cancer is getting worse or better.
Timeline
- Start
- 2002-10
- Primary completion
- 2006-09
- Completion
- 2006-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | 400 mg | Oral |